generic glycemic control drugs

 

Published July 2017  ·  Report No. GCD229F · Price US $875

 


The market for glycemic control continues to grow globally at rates that are alarming to public health officials. Over the past decade, prevalence of diabetes among adults has increased by 33 percent. In the United States, approximately 6 percent of the population (i.e., 16 million people) has diabetes and it is the fourth-leading cause of death by disease. Among Americans in their thirties, diabetes has increased by 70 percent in the past 10 years. Each year, approximately 800,000 people in the US -and three times this number worldwide – are diagnosed with diabetes. However, one-third of the people afflicted are currently undiagnosed. As glycemic control drugs reach the end of their patent life, activity in the generic glycemic control segment will intensify.

 

 

Report Brochure (Download PDF)

 

Report Order Form (Download PDF)

 


Generic Glycemic Control Drugs – Content Highlights

  • Provides detailed analysis of generic glycemic control drugs indicated for the treatment of high blood glucose
  • Presents the competitive picture for generic glycemic control drugs
  • Evaluates the importance of ANDA filing strategies and indirect ANDA acquisition on participant growth prospects
  • Analyzes the impact of patents, exclusivity and litigation on participant market sector prospects
  • Assesses the market presence and product position of the top generic glycemic control drug suppliers

Generic Glycemic Control Drugs – Summary of Contents

Generic Markets Overview

 

Major Market Segments for Generic Drugs

FDA Approved Generic Drugs by Therapeutic Class

DrugClasses for Generic Glycemic Control Drugs

Generic Glycemic Control Drugs – Approved Product Charts

The Current Landscape

Glycemic Control Generics – Product Maps & Competitive Index

Acarbose

Glimepiride

Glipizide

Glyburide

Metformin

Metformin Combination Drugs

Nateglinide

Repaglinide

Pioglitazone

 

Company Activity Maps

 

Key Generic Drug Opportunity Factors

Saturation Index

API Opportunity Index

P(iv) Glycemic Control Drug Index

Orange Book Glycemic Control Drug Patent Staircase Analysis

 

Generic Glycemic Control Drugs – Company Activity Maps

Detailed Charts for top 25 Generic Glycemic Control Participants